Lilly Sees More Dealmaking as GLP-1 Wins Expand Market
Eli Lilly’s GLP-1 drugs have changed the game in obesity and diabetes. This article explains why Lilly Sees More Deal...
Why index readings matter: they provide a concise pulse on market health, guiding timely adjustments to risk and allocation.
21,223 articlesEli Lilly’s GLP-1 drugs have changed the game in obesity and diabetes. This article explains why Lilly Sees More Deal...
After a staggering 453% surge, investors face a crossroads: take profits now or double down on a company reshaping th...
New data shows Baby Boomers control a large share of U.S. wealth and wield outsized influence, even as anxiety about ...
When a top executive sells a chunk of stock, it draws attention. This guide examines brian chesky just sold, what ins...
The latest weekly data shows a spike in initial claims, but the broader labor market remains resilient. Analysts warn...
When a biotech CEO sells shares after exercising options, investors rightly pause to interpret the move. This article...
High-profile legal headlines can ripple into everyday money matters. This article uses the James Harden case to illus...
Explore how Jean Eric Salata leads EQT Group to build durable value across private equity and beyond. This article di...
A long-remembered jab about Chrome’s prospects resurfaces as the browser landscape continues to evolve. Here’s what i...
A sudden antivirus alert can look legitimate—until you realize it's a scam. This article breaks down how these tricks...
By late 2025, roughly 12% of U.S. adults were using GLP-1 weight-loss medications, a trend that is quietly trimming g...
Cathie Wood goes bargain as Ark trims some bets and adds to three promising names. This piece breaks down the three s...